VCTX210: gene-edited stem-cell-derived pancreatic cells in an implanted device
What this study tests
A first-in-human Phase 1 study of gene-edited, stem-cell-derived pancreatic cells in an implanted device, intended to function without immunosuppression. The seven-participant study completed in 2023. No registry-posted or peer-reviewed outcomes were identified in this review, so completion does not establish safety or immune evasion.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2023-06-26.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults 18-65 with type 1 diabetes for at least 5 years on a stable, optimized insulin regimen for at least 3 months. Excluded: prior islet/organ transplant, 2 or more severe low-blood-sugar (hypoglycemic) events in the past 6 months, recent immunosuppressant use, or prior gene therapy. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results are posted to the registry, and no peer-reviewed outcome paper was identified in this review. The safety-focused design and completion of the study are not evidence that the intended immune evasion or insulin production was achieved.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: Canada. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Primary endpoints
- Incidence of adverse events with causality related to the VCTX210A units and/or the surgical implantation/explantation procedures, assessed through 6 months post-implantation
The full picture
Study design
VCTX210 combined gene-edited pancreatic cells with a removable implant. The intended use was insulin production without immunosuppressive medicines; the first-dosing announcement describes an investigational design, not a clinical result.2
The open-label Phase 1 study enrolled seven adults in Canada and completed in January 2023. Its primary endpoint was adverse events related to the product or implantation/removal procedures through six months.1
Evidence available
No registry results or peer-reviewed outcome paper were identified. The study therefore cannot be presented as demonstrated immune evasion, established safety, or effective insulin replacement. Subsequent development of related candidates does not fill this evidence gap.
Sources
- [1]NCT05210530: study record · Trial registry — Current status, study design and eligibility checked 16 September 2026; this does not imply posted outcomes.
ClinicalTrials.gov, NCT05210530.
- [2]CRISPR Therapeutics and ViaCyte: first VCTX210 participant dosed · Manufacturer
CRISPR Therapeutics and ViaCyte, first-dosing announcement (2022).